We are live on ! Find out more
NAGE

Niagen Bioscience

78 hedge funds and large institutions have $45.1M invested in Niagen Bioscience in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more call options, than puts

Call options by funds: $379K | Put options by funds: $173K

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

40% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 15

16% more funds holding

Funds holding: 6778 (+11)

4.45% more ownership

Funds ownership: 17.43%21.88% (+4.4%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1% less capital invested

Capital invested by funds: $45.7M → $45.1M (-$560K)

Holders
78
Holders Change
+11
Holders Change %
+16.42%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
28
Increased
21
Reduced
15
Closed
16
Calls
$379K
Puts
$173K
Net Calls
+$206K
Net Calls Change
-$48K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$9.24M +$1.13M +338,306 +11%
BlackRock
2
BlackRock
New York
$8.51M +$7.41M +2,213,225 +245%
TCM
3
Tieton Capital Management
Washington
$8.1M -$180K -53,815 -2%
IC
4
Iconiq Capital
California
$3.54M
Geode Capital Management
5
Geode Capital Management
Massachusetts
$3.09M +$1.91M +570,570 +102%
State Street
6
State Street
Massachusetts
$1.52M +$1.22M +365,097 +192%
Renaissance Technologies
7
Renaissance Technologies
New York
$1.14M +$108K +32,400 +8%
JP Morgan Chase
8
JP Morgan Chase
New York
$816K +$836K +249,784 +510%
GI
9
GAMCO Investors
Connecticut
$637K -$103K -30,700 -12%
WG
10
Winton Group
United Kingdom
$597K +$732K +218,857 New
GF
11
Gabelli Funds
New York
$546K
Royal Bank of Canada
12
Royal Bank of Canada
Ontario, Canada
$545K +$48.8K +14,579 +8%
Millennium Management
13
Millennium Management
New York
$525K -$1.31M -391,941 -67%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$520K +$401K +119,915 +170%
Connor, Clark & Lunn Investment Management (CC&L)
15
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$431K +$83.6K +24,991 +19%
Charles Schwab
16
Charles Schwab
California
$383K +$386K +115,502 +468%
UBS Group
17
UBS Group
Switzerland
$382K +$401K +119,723 +598%
Cambridge Investment Research Advisors
18
Cambridge Investment Research Advisors
Iowa
$313K -$28.4K -8,500 -7%
Northern Trust
19
Northern Trust
Illinois
$295K +$25.3K +7,568 +8%
SO
20
STRS Ohio
Ohio
$284K +$348K +104,100 New
Invesco
21
Invesco
Georgia
$245K +$300K +89,719 New
SBCM
22
Silverberg Bernstein Capital Management
New York
$224K
Goldman Sachs
23
Goldman Sachs
New York
$206K -$391K -116,757 -61%
Man Group
24
Man Group
United Kingdom
$203K +$190K +56,764 +324%
Morgan Stanley
25
Morgan Stanley
New York
$190K +$83.6K +24,991 +56%

NAGE Hedge Fund Activity: Q2 2024 in Review

78 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2024, worth a combined $45.1M — down 1.2% from $45.7M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new NAGE positions and 16 closed out — a net gain of 12 holders — while 21 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $7.41M. The largest seller was Millennium Management, cutting an estimated $1.31M.

  • 78 institutional investors held Niagen Bioscience (NAGE) as of Q2 2024, up from 67 in Q1 2024.
  • Funds reported $45.1M of Niagen Bioscience stock for Q2 2024, down 1.2% quarter-over-quarter.
  • 28 funds opened new Niagen Bioscience positions in Q2 2024 and 16 closed out, a net change of +12 holders.
  • The largest Niagen Bioscience buyer in Q2 2024 was BlackRock, an estimated $7.41M added.
  • The largest Niagen Bioscience seller in Q2 2024 was Millennium Management, an estimated $1.31M sold.

Based on aggregated 13F filings for Q2 2024.